Perbedaan Kadar Interferon Gamma Cairan Asites Pada Subtipe Histopatologi Serosa dan Non-Serosa Kanker Ovarium Tipe Epitel

https://doi.org/10.22146/jkr.44182

Anindita Kurniasari(1*), Moh Nailul Fahmi(2), Nungki Anggorowati(3)

(1) Mahasiswa Program Sarjana Kedokteran, FK-KMK, UGM
(2) Departemen Obstetri dan Ginekologi, FK-KMK, UGM
(3) Departemen Patologi Anatomi FKKMK UGM
(*) Corresponding Author

Abstract


Latar Belakang: Karsinoma ovarium dapat dibedakan menjadi subtipe serosa dan non-serosa, dimana subtipe serosa memiliki prognosis yang lebih baik. IFN-γ dapat memiliki aktivitas pro-tumor maupun anti-tumor. Penelitian tentang kadar IFN-γ asites serta hubungannya dengan subtipe serosa dan non-serosa belum banyak dilakukan.

Tujuan: Mengetahui perbedaan rata-rata kadar IFN-γ cairan asites pada subtipe serosa dan non-serosa karsinoma ovarium.

Metode: Penelitian cross sectional selama periode September – Desember 2018. Pengambilan sampel asites dilakukan di kamar operasi RSUP Dr. Sardjito dan pengujian sitokin menggunakan Human IFN-γ ELISA Kit dilakukan di Laboratorium Biologi Molekuler FKKMK Universitas Gadjah Mada.

Hasil dan Pembahasan: Pada 11 sampel subtipe serosa didapatkan rata-rata kadar IFN-γ sebesar 0,46 pg/ml, sedangkan pada 7 sampel non-serosa didapatkan rata-rata 0,97 pg/ml, namun perbedaan rata-rata tersebut tidak signifikan secara statistik (p=0,104).

Simpulan: Tidak terdapat perbedaan rata-rata kadar IFN-γ dalam cairan asites pada subtipe serosa dan non-serosa karsinoma ovarium.

Kata Kunci: interferon gamma (IFN-γ), karsinoma ovarium, asites, subtipe histopatologi


Keywords


interferon gamma (IFN-γ); karsinoma ovarium; asites; subtipe histopatologi

Full Text:

PDF


References

  1. Marth, C., Fiegl, H., Zeimet, A.G., Müller-Holzner, E., Deibl, M., Doppler, W. and Daxenbichler, G., 2004. Interferon-γ expression is an independent prognostic factor in ovarian cancer. American journal of obstetrics and gynecology191(5), pp.1598-1605.
  2. American Cancer Society 2018, Key Statistics for Ovarian Cancer, Atlanta: American Cancer Society, Inc. 2018, viewed 21 April 2018, https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html
  3. World Health Organization 2014, Cancer Country Profiles, viewed 21 April 2018, https://www.who.int/cancer/country-profiles/idn_en.pdf
  4. Ezzati, M., Abdullah, A., Shariftabrizi, A., Hou, J., Kopf, M., Stedman, J.K., Samuelson, R. and Shahabi, S., 2014. Recent advancements in prognostic factors of epithelial ovarian carcinoma. International scholarly research notices2014.
  5. Reid, B.M., Permuth, J.B. and Sellers, T.A., 2017. Epidemiology of ovarian cancer: a review. Cancer biology & medicine14(1), p.9.
  6. World Health Organization, 2014. WHO Classification of Tumors of Female Reproductive Organs. 4th Edition, p.15-40.
  7. Mizuno, M., Kajiyama, H., Shibata, K., Mizuno, K., Kawai, M., Nagasaka, T. and Kikkawa, F., 2015. Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients. British journal of cancer112(8), p.1376.
  8. Ahmed, N. and Stenvers, K., 2013. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Frontiers in oncology3, p.256.
  9. Chen, Y.L., Cheng, W.F., Chang, M.C., Lin, H.W., Huang, C.T., Chien, C.L. and Chen, C.A., 2013. Interferon gamma in ascites could be a predictive biomarker of outcome in ovarian carcinoma. Gynecologic oncology131(1), pp.63-68.
  10. Hosono, S., Kajiyama, H., Mizuno, K., Sakakibara, K., Matsuzawa, K., Takeda, A., Kawai, M., Nagasaka, T. and Kikkawa, F., 2011. Comparison between serous and non-serous ovarian cancer as a prognostic factor in advanced epithelial ovarian carcinoma after primary debulking surgery. International journal of clinical oncology16(5), p.524.
  11. Mojic, M., Takeda, K. and Hayakawa, Y., 2017. The dark side of IFN-γ: its role in promoting cancer immunoevasion. International journal of molecular sciences19(1), p.89.
  12. Alspach, E., Lussier, D.M. and Schreiber, R.D., 2018. Interferon γ and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity. Cold Spring Harbor perspectives in biology, p.a028480.
  13. Ricci, F., Affatato, R., Carrassa, L. and Damia, G., 2018. Recent insights into mucinous ovarian carcinoma. International journal of molecular sciences19(6), p.1569.
  14. Ku, F.C., Wu, R.C., Yang, L.Y., Tang, Y.H., Chang, W.Y., Yang, J.E., Wang, C.C., Jung, S.M., Lin, C.T., Chang, T.C. and Chao, A., 2018. Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: Results from a single-center Taiwanese study. Journal of the Formosan Medical Association117(2), pp.117-125.
  15. Tan, D.S. and Kaye, S., 2007. Ovarian clear cell adenocarcinoma: a continuing enigma. Journal of clinical pathology60(4), pp.355-360.



DOI: https://doi.org/10.22146/jkr.44182

Article Metrics

Abstract views : 166 | views : 105

Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 The Author(s)

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Jurnal Kesehatan Reproduksi Indexed by:

 



SEKRETARIAT JURNAL KESEHATAN REPRODUKSI
Departemen Obstetri dan Ginekologi, FK-KMK, UGM/RS Dr. Sardjito
Jl. Kesehatan No. 1, Sekip Utara, Yogyakarta 55281
Tlp: (0274) 511329 / Faks: (0274) 544003
Email: jurnal.kesehatanreproduksi@ugm.ac.id
Cp: Dwi Astuti +6281802698043